With regard to this, several small molecule inhibitors and activators of myosin have been developed for treating inherited cardiomyopathies with genetic variants in myosin and entered different phases of clinic trails (Lehman et al., 2022). The gene discussed is MYH14; the disease is cardiomyopathy.